Skip to main content
. 2025 Aug 7;13(1):e65. doi: 10.22037/aaemj.v13i1.2730

Table 1.

Comparing the baseline characteristics of studied patients between the 4 groups according to stress hyperglycemia ratio (SHR) and hemoglobin-to-red blood cell distribution width ratio (HB/RDW) levels (n=345)

Characteristic High SHR (≥1.18) -- low HB/RDW (≤0.76) P
No--No (n= 180) No--Yes (n=53) Yes--No (n=75) Yes--Yes (n=37)
Age, years
Mean ± SD 59.49 ± 14.91 64.55 ± 16.59 62.51 ± 13.56 67.46 ± 16.23 0.011
Sex
Male 100 (55.56) 27 (50.94) 42 (56.00) 14 (37.84) 0.241
Female 80 (44.44) 26 (49.06) 33 (44.00) 23 (62.16)
Comorbidities
Smoking 69 (38.33) 14 (26.42) 29 (38.67) 11 (29.73) 0.346
Current alcohol drinking 74 (41.11) 18 (33.96) 37 (49.33) 13 (35.14) 0.297
Prior stroke 20 (11.11) 6 (11.32) 6 (8.00) 9 (24.32) 0.109
Atrial fibrillation 41 (22.78) 19 (35.85) 28 (37.33) 14 (37.84) 0.034
Myocardial infarction 10 (5.56) 6 (11.32) 5 (6.67) 8 (21.62) 0.017
Chronic heart failure 12 (6.67) 13 (24.53) 6 (8.00) 6 (16.22) 0.002
Diabetes mellitus 39 (21.67) 12 (22.64) 28 (37.33) 14 (37.84) 0.025
Hypertension 116 (64.44) 39 (73.58) 59 (78.67) 29 (78.38) 0.081
Chronic kidney disease 17 (9.44) 14 (26.42) 6 (8.00) 7 (18.92) 0.006
History of malignancy 3 (1.67) 2 (3.77) 0 (0.00) 3 (8.11) 0.031
Dyslipidemia 77 (42.78) 10 (18.87) 37 (49.33) 17 (45.95) 0.003
Preexisting dependency
Yes (mRS 3-5) 2 (1.11) 5 (9.43) 3 (4.00) 3 (8.11) 0.007
Onset to treatment time (minutes)
Mean ± SD 145.36 ± 58.21 136.89 ± 46.52 133.28 ± 60.59 150.65 ± 58.04 0.304
< 3 hours 127 (70.56) 45 (84.91) 62 (82.67) 22 (59.46) 0.010
3-4.5 hours 53 (29.44) 8 (15.09) 13 (17.33) 15 (40.54)
Onset to door (minutes)
Mean ± SD 94.48±51.36 82.30±37.85 89.97±53.91 107.27±57.76 0.178
Blood pressure at admission (mmHg)
Systolic 156.46± 26.12 154.98±28.38 164.53±32.14 167.81±33.03 0.034
Diastolic 91.67±17.70 90.51±18.46 96.53±22.22 92.19±19.81 0.191
Admitted NIHSS
Mean ± SD 11.17 ± 4.88 12.26 ± 5.76 14.60 ± 6.29 15.13 ± 5.77 <0.001
5-15 143 (79.44) 34 (64.15) 40 (53.33) 15 (40.54) <0.001
16-20 30 (16.67) 15 (28.30) 16 (21.33) 15 (40.54)
>20 7 (3.89) 4 (7.55) 19 (25.33) 7 (18.92)
TOAST classification
Large artery atherosclerosis 33 (18.33) 7 (13.21) 23 (30.67) 13 (35.14) 0.001
Cardioembolic stroke 49 (27.22) 22 (41.51) 31 (41.33) 17 (45.95)
Small-vessel occlusion 89 (49.44) 20 (37.74) 18 (24.00) 7 (18.92)
Stroke of other determined etiology 4 (2.22) 3 (5.66) 2 (2.67) 0 (0.00)
Stroke of undetermined etiology 5 (2.78) 1 (1.89) 1 (1.33) 0 (0.00)
Baseline ASPECTS
Median (IQR) 10 (9 - 10) 9 (8 - 10) 9 (7 - 10) 8 (7 - 10) <0.001
Hospital stays (days)
Median (IQR) 5 (3 - 8) 5 (4 - 11) 5 (3 - 9) 8 (4 - 17) 0.021
Laboratory data
WBC (103cells/mm3) 8.68±2.23 8.89±2.74 9.39±3.05 9.53± 6.27 0.301
Platelet (103cells/mm3) 249.68±60.61 249.94±71.91 249.84±83.81 252.24±125.93 0.230
Creatinine (mg/dL) 0.99±0.47 1.52±1.59 0.98±0.30 1.09±0.50 <0.001
Admission plasma glucose (mg/dL) 123.63±53.50 119.59±56.56 165.41±69.57 168.35±77.27 <0.001

Values are presented as mean ± standard deviation (SD), frequency (percentage), or median (interquartile range (IQR)). mRS: modified Rankin Score; NIHSS: National Institutes of Health Stroke Scale; TOAST: trial of ORG 10172 in acute stroke treatment; WBC: white blood cell; ASPECTS: Alberta Stroke Program Early CT Score.